Ozempic and Wegovy pumped $26 billion into Novo Nordisk last year. Can the pharma giant find its next breakthrough before the boom ends?

Novo Nordisk’s Worst Month Since 2002 Highlights Growth Concerns

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Ozempic and Wegovy pumped $26 billion into Novo Nordisk last year. Can the pharma giant find its next breakthrough before the boom ends?

The Danish drugmaker is investing billions to prepare for the day when its weight-loss and diabetes drug patents expire.

For the first time, Ekstra Bladet was given the opportunity to ask questions to a Novo Nordisk official in the wake of the revelation of how migrant workers have been exploited and underpaid on Novo Nordisk's construction sites.